Van Wart, Scott
Mager, Donald E.
Bednasz, Cindy J.
Huizing, Marjan http://orcid.org/0000-0002-9375-9539
Carrillo, Nuria http://orcid.org/0000-0003-0374-0808
Funding for this research was provided by:
National Human Genome Research Institute
Escala Therapeutics, Inc.
Article History
Accepted: 10 March 2021
First Online: 24 April 2021
Declarations
:
: This study was supported by the Intramural Research Program of the National Human Genome Research Institute (NHGRI), National Institutes of Health, Bethesda, Maryland, United States and by a Cooperative Research and Development Agreement with Escala Therapeutics, Inc.
: This study was partially funded through Cooperative Research and Development Agreements (CRADA) with Escala Therapeutics, Inc. Dr Huizing is a co-inventor on patent US Patent No. 8,410,063. “<i>N-acetylmannosamine as a Therapeutic Agent</i>”.
: The protocols were approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board (IRB).
: All subjects provided written, informed consent.
: Not applicable.
: Data is available upon request.
: NONMEM model code provided in Supplemental File.
: Nuria Carrillo and Marjan Huizing were involved in study planning, conduct and data collection as well as manuscript preparation. Scott Van Wart, Donald E. Mager, and Cindy Bednasz were involved with study planning, data analysis and manuscript writing. All authors read and approved the final manuscript.